Integer leverages its manufacturing and design capabilities to provide end-to-end solutions from component manufacturing to full device development. The company focuses on high-potential end markets with a proven track record of above-market organic growth and margin expansion through operational excellence and strategic acquisitions.
Cyborg Score Rationale
Strong financial performance in 2024 with 10.35% revenue growth and 32% earnings growth, but recent guidance revision to flat 2026 sales and earnings caused a significant 32% stock decline in October 2025. Recovery outlook depends on execution of strategic initiatives and market demand stabilization.
Top Insights
2024 revenue grew 10.35% to $1.72B with earnings increasing 32.26% to $119.90M, demonstrating operational leverage
Stock declined 32% on October 23, 2025 following 2026 guidance revision to flat growth, creating market uncertainty
Analyst consensus remains bullish with average "Buy" rating and 12-month price target of $93.71 (28.86% upside potential)
Company focuses on high-potential end markets including interventional cardiology, cardiac rhythm management, and neuromodulation with diversified product portfolio
Named Competitors
Medical Device Outsourcing — Diversified electronics and medical device manufacturing services
Medical Device Contract Manufacturing — Global electronics manufacturing services with medical device focus
Implantable Device Manufacturing — Specialized contract manufacturing for implantable medical devices
Recent Developments
(October 2025) CEO Khales Payman purchased 3,127 shares at 52-week low of $62 per share
(October 2025) Stock declined 32% following 2026 guidance revision to flat sales and earnings
(July 2024) Company achieved strong Q2 2025 financial performance with margin expansion and reaffirmed guidance
Open the full interactive Integer Holdings Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.